Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Published:2022-05-15 Issue:10 Volume:205 Page:1228-1235
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

De Jager Veronique¹^ORCID,Gupte Nikhil²³,Nunes Silvia¹,Barnes Grace L.²,van Wijk Rob Christiaan⁴^ORCID,Mostert Joni¹,Dorman Susan E.⁵,Abulfathi Ahmed A.⁶⁷,Upton Caryn M.¹,Faraj Alan⁴,Nuermberger Eric L.²,Lamichhane Gyanu²,Svensson Elin M.⁸⁹^ORCID,Simonsson Ulrika S. H.⁴^ORCID,Diacon Andreas H.¹,Dooley Kelly E.²^ORCID

Affiliation:

1. TASK Applied Science, Cape Town, South Africa;

2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland;

3. Johns Hopkins India, Pune, India;

4. Department of Pharmaceutical Biosciences and

5. Medical University of South Carolina, Charleston, South Carolina;

6. Department of Medicine, Stellenbosch University, Cape Town, South Africa;

7. Department of Clinical Pharmacology and Therapeutics, University of Maiduguri, Maiduguri, Nigeria; and

8. Department of Pharmacy, Uppsala University, Uppsala, Sweden;

9. Department of Pharmacy, Radboud University, Njimegen, the Netherlands

Funder

Vetenskapsrådet

National Institute of Allergy and Infectious Diseases

U.S. Food and Drug Administration

Swedish National Infrastructure for Computing

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202108-1976OC

Reference23 articles.

1. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

2. Irreversible Inhibition of the Mycobacterium tuberculosis β-Lactamase by Clavulanate

3. Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

4. Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus

5. Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable β-Lactam Antibiotic

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling;CPT: Pharmacometrics & Systems Pharmacology;2023-12-15

2. The MSMEG_1586 of M. smegmatis Is a Penicillin-Interactive Enzyme That Can Potentially Hydrolyse Aztreonam and Cephalosporins;Current Microbiology;2023-12-02

3. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen;International Journal of Antimicrobial Agents;2023-12

4. In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex;Microbiology Spectrum;2023-10-17

5. The In vitro activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review;INT J MYCOBACT;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3